Cortexin Peptide Reduced Brain Damage After Stroke by Lowering Oxidative Stress in Rats

35 male Wistar rats divided into 5 groups: control, ischemia only (45 minutes), ischemia-reperfusion (7 days), and two Cortexin treatment groups (1 mg/kg and 2 mg/kg during reperfusion). On day 8, brain tissue was analyzed by immunohistochemistry for OPG, RANK, RANKL, and TRPC1 expression. Serum total oxidant status (TOS) and total antioxidant status (TAS) were measured by ELISA.

Stroke is a leading cause of death and disability worldwide, and the damage that occurs when blood flow is restored (reperfusion injury) has no targeted treatment. Cortexin has been used clinically in Russia and some Eastern European countries for decades for neurological conditions, but its mechanisms have been poorly understood. This study provides molecular evidence for how it might protect the brain — through antioxidant effects and modulation of inflammatory and calcium signaling pathways — which could support its investigation in more rigorous clinical trials.

Cortexin is part of a tradition of peptide bioregulators developed primarily in Russian science — preparations derived from animal organ tissues that contain mixtures of short peptides. While widely used in some countries, they lack the rigorous Phase III trial data required for approval in Western markets. This study contributes to a growing body of mechanistic research attempting to explain how these preparations work at the molecular level, potentially bridging the gap between traditional use and evidence-based medicine.

This was a small animal study (35 rats, 7 per group), which limits statistical power. The abstract contains apparent formatting errors in the p-values, making some results difficult to interpret. Cortexin is a complex mixture of peptides, not a single defined molecule, which complicates mechanistic interpretation. The 7-day treatment period is short. No behavioral or functional outcomes were measured — only biomarker expression. The study was not blinded according to the abstract. Results from rat stroke models frequently fail to translate to human stroke treatment.